OBJECTIVE: SMFM and ACOG guidelines recommend comprehensive prenatal diagnosis in pregnancy. Upon detection of structural abnormalities during the anatomic ultrasound, it is recommended that women undergo counseling including the opportunity for additional diagnostic testing including chromosomal microarray analysis (CMA). With the added prognostic value of a significant CMA abnormality, some women may desire pregnancy termination.
However, twenty states have enacted laws prohibiting abortion beyond 20 weeks' gestation; currently 17 are active. We sought to estimate the effect of 20-week abortion bans on health outcomes and costs in the setting of a fetal diagnosis from microarray with an underlying structural anomaly. STUDY DESIGN: A decision-analytic model was built using TreeAge software to evaluate the impact of a 20-week ban on abortion in a theoretical cohort of 10,000 women with abnormal CMA after identification of structural abnormalities on ultrasound. Outcomes included number of abortions, maternal death, neonatal death, intrauterine fetal demise, and a child with moderate or severe chromosomal microdeletions, in addition to cost and quality-adjustedlife-years (QALY). The threshold for cost-effectiveness was set to $100,000 per QALY. Sensitivity analyses were performed broadly. RESULTS: In this hypothetical cohort, a 20-week abortion ban results in an additional 217 stillbirths, 337 neonatal deaths. There would be 1,823 fewer terminations of pregnancy. The presence of a ban results in 48,148 fewer maternal QALYs and costs society over $3.3 billion. Among the 5,958 women who would consider termination, 1,650 would still travel out of state to obtain the abortion. In sensitivity analyses, not having a ban in place remained the cost-effective strategy until abortion cost over 920 times its current cost. CONCLUSION: Policies prohibiting termination of pregnancy after 20 weeks' gestation are associated with significant societal costs and worsened maternal outcomes when considering a population of women with abnormal ultrasound and CMA. With increased utilization and improved resolution of CMA testing, the magnitude of this impact may increase.
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